Can cervical cancer patients stop immunotherapy early? new study investigates
NCT ID NCT07645625
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study follows 261 people with persistent, recurrent, or metastatic cervical cancer who are taking pembrolizumab (Keytruda) with or without bevacizumab (Avastin). Some participants may choose to stop pembrolizumab early if their tumor shrinks or disappears, while others continue standard treatment. Researchers will track how long the cancer stays under control and compare results to previous trials, aiming to see if early discontinuation is a safe option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) with or without bevacizumab (Avastin)
What this could lead to
If successful, this could show that stopping pembrolizumab early is safe and effective for some patients with advanced cervical cancer, potentially reducing treatment burden.
What could go wrong
This is an observational registry, not a controlled trial, so results may be less definitive. Early discontinuation might lead to higher relapse risk, and findings may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC
NOT_YET_RECRUITINGAmsterdam, Netherlands
Contact Email: •••••@•••••
Contact
-
Antoni van Leeuwenhoek Ziekenhuis
NOT_YET_RECRUITINGAmsterdam, Netherlands
Contact Email: •••••@•••••
Contact
-
Catharina Ziekenhuis
RECRUITINGEindhoven, Netherlands
Contact Email: •••••@•••••
Contact
-
Erasmus MC
NOT_YET_RECRUITINGRotterdam, Netherlands
Contact Email: •••••@•••••
Contact
-
Isala Klinieken
NOT_YET_RECRUITINGZwolle, Netherlands
Contact Email: •••••@•••••
Contact
-
LUMC
RECRUITINGLeiden, Netherlands
Contact Email: •••••@•••••
Contact
-
Maastricht UMC
NOT_YET_RECRUITINGMaastricht, Netherlands
Contact Email: •••••@•••••
Contact
-
Medisch Spectrum Twente
NOT_YET_RECRUITINGEnschede, Netherlands
Contact Email: •••••@•••••
Contact
-
Radboud UMC
NOT_YET_RECRUITINGNijmegen, Netherlands
Contact Email: •••••@•••••
Contact
-
UMC Utrecht
NOT_YET_RECRUITINGUtrecht, Netherlands
Contact Email: •••••@•••••
Contact
-
University Mecdical Center Groningen
RECRUITINGGroningen, 9713 GZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact